the authors designed a clinical trial to assess the impact of aspirin ( asa ) ( 600 mg four times daily ) on the constitutional sequelae of recombinant leukocyte a interferon ( ifn-alpha 2a ) , 20 x 10 ( 6 ) u/m2 thrice weekly , in 29 patients with advanced renal cell cancer ( rcc ) .
C0021734
ifn-alpha 2a
C0007134
renal cell cancer